Table.

	n/NAR	IR
Treatment emergent AE	3391/3770	25.8
Serious AE (including death)	940/3770	7.2
Temporary d/c due to AE	1241/3647	9.5
Permanent d/c due to AE	644/3770	4.8
Death	69/3770	0.52
Serious infection	344/3770	2.7
Opportunistic infection (excluding tuberculosis, including multidermatomal herpes zoster)	59/3770	0.44
Herpes zoster	384/3770	3.0
Tuberculosis	20/3770	0.15
Major adverse cardiovascular events*	63/3251	0.50
DVT	41/3770	0.31
PE	32/3770	0.24
DVT and/or PE	60/3770	0.45
Malignancies excluding NMSC	120/3770	0.90
NMSC	44/3770	0.33
Lymphoma	8/3770	0.06
Gastrointestinal perforation	6/3770	0.04

*studies with positive adjudication. AE=adverse event; D/C= discontinuation; DVT=deep vein thrombosis; IR=incidence rate; NAR=number of patients at risk; NMSC=non-melanoma skin cancer; PE=pulmonary embolism